AMP-activated protein kinase (AMPK) is a principal metabolic regulator affecting growth and response to cellular stress. Comprised of catalytic and regulatory subunits, each present in multiple forms, AMPK is best described as a family of related enzymes. In recent years, AMPK has emerged as a desirable target for modulation of numerous diseases, yet clinical therapies remain elusive. Challenges result, in part, from an incomplete understanding of the structure and function of full-length heterotrimeric complexes. In this work, we provide the full-length structure of the widely expressed a1b1g1 isoform of mammalian AMPK, along with detailed kinetic and biophysical characterization. We characterize binding of the broadly studied synthetic activator A769662 and its analogs. Our studies follow on the heels of the recent disclosure of the a2b1g1 structure and provide insight into the distinct molecular mechanisms of AMPK regulation by AMP and A769662.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a central monitor and regulator of cellular energy status in eukaryotes. From a functional perspective, conditions of energy depletion cause activation of AMPK that leads to upregulation of catabolic processes (fatty acid oxidation and glycolysis) and a corresponding downregulation of anabolic processes (cholesterol and lipid synthesis and gluconeogenesis). The net effect is to replenish ATP at times of stress so that cellular energy balance is restored (Carling et al., 2011; Hardie, 2007; Oakhill et al., 2012; Steinberg and Kemp, 2009) . Given this central function in metabolism, AMPK has emerged as an attractive target for diabetes and cancer (Hardie, 2013; Viollet et al., 2007) . Pharmacological activation of AMPK has long been sought as a therapeutic approach in these disorders, yet clinically viable direct small molecule activators of AMPK have to date remained elusive. This is, in part, due to the complexity of this enzyme and the lack of detailed understanding of its molecular mode of action.
In recent years, there has been significant progress in elucidating the structural basis of these complex and critical functions. AMPK is a 145 kDa heterotrimeric serine/threonine kinase comprised of one catalytic a subunit in complex with regulatory b and g subunits. The a subunit includes an N-terminal kinase domain (KD), which is the catalytic engine of the enzyme, and a C-terminal subunit-interacting domain (SID) that plays a structural role in mediating interactions with b and g. Between these regions lies an auto-inhibitory domain (AID) comprised of a three-helical bundle, as well as regulatory motifs termed the a regulatory subunit-interacting motifs (RIMs), which appear to have a critical role in allosteric regulation of AMPK by nucleotides (Chen et al., 2013; Xiao et al., 2011) . a-N-myristoylation of the b subunit may facilitate reversible binding to membranes and activation by upstream kinases (Oakhill et al., 2010; Steinberg and Kemp, 2009; Warden et al., 2001) . The unstructured N-terminal portion of this domain is followed by a b sheet rich carbohydrate binding module (CBM). This motif bears sequence similarity to starch binding domains in other proteins and interacts with glycogen and b-cyclodextrin, a cyclized form of maltoheptaose (Polekhina et al., 2005) . The most C-terminal element of the b subunit serves as a scaffold, forming an extended b sheet with a and g subunits within the regulatory core. Finally, the g subunit is comprised of four tandem cystathionine b synthase (CBS) motifs, which are structural modules of 60 amino acids organized into a two-stranded b sheet with two surrounding a helices. A pair of CBS modules forms a ''Bateman'' domain, which possesses two nucleotide binding sites, one on each side.
The presence of multiple gene products (a1, a2; b1, b2; g1, g2, g3) theoretically allows subunits to be mixed-and-matched to create twelve unique heterotrimers. The distinct activities of each complex are not fully understood, but derive, in part, from differential expression patterns across tissues. For example, g1 and g2 appear to be widely expressed, while g3 appears restricted to skeletal muscle (Birk and Wojtaszewski, 2006; Cheung et al., 2000) . In addition, expression patterns may differ across species, as human liver predominantly contains the a1b2g1 heterotrimer, while rat and dog livers mainly contain a2b1g1 and a1b1g1 respectively (Wu et al., 2013) . A full understanding of the biological function of AMPK will require structural characterization of the different heterotrimers and assignment of their cell-and tissue-specific functions.
Activity of AMPK has generally been thought to require phosphorylation on a conserved threonine (T172) within the activation loop by upstream kinases, LKB1, or CaMKKb, leading to >500-fold stimulation of its activity (Hawley et al., 1996 (Hawley et al., , 2005 Hurley, et al., 2005; Shaw et al., 2004; Woods et al., 2003a Woods et al., , 2005 . However, recent work has revealed that under certain conditions, AMPK that is unphosphorylated on T172 of the activation loop is still competent to phosphorylate SAMS peptide (Scott et al., 2014) . Catalytic activity can be further modulated by interactions with adenine nucleotides in the g subunit. Binding of ATP is regarded as inhibitory, while AMP and ADP appear stimulatory. Stimulation occurs principally through protection of T172 from dephosphorylation by phosphatases, with additional allosteric activation triggered by AMP (Gowans et al., 2013; Hardie, 2011; Steinberg and Kemp, 2009) .
The capacity to be activated by nucleotides was an original defining feature of AMPK Steinberg and Kemp, 2009 ), but the first synthetic activator was not reported until 2006 (Cool et al., 2006) . When administered to ob/ob mice, this thienopyridone derivative, termed A769662, was observed to lower blood glucose, decrease body weight, and reduce circulating levels of triglycerides. A769662 was shown to mediate its effects through direct interaction with AMPK with in vitro potency in the nanomolar range. In addition, mutagenesis and biophysical experiments suggested that the site of binding and mechanism of activation differ between A769662 and AMP (Cool et al., 2006; Gö ransson et al., 2007; Landgraf et al., 2013; Sanders et al., 2007; Scott et al., 2008) .
Structural insights into AMPK function have been derived largely from studies involving isolated domains or truncations. A breakthrough came with the identification of the structure of the regulatory core particle comprising the g subunit and C-terminal portions of the a and b chains (Amodeo et al., 2007; Chen et al., 2012; Townley and Shapiro, 2007; Xiao et al., 2007) . These studies revealed the structure of the four nucleotide binding sites in the g subunit and set the stage for understanding differential binding to each of these pockets (Chen et al., 2012; Kemp et al., 2007; Xiao et al., 2007 Xiao et al., , 2011 .
Despite shedding light on the topology of the g subunit, structures that lack the KD do not provide information on how nucleotide binding is coupled to changes in activity. In 2011, progress toward this goal was made with the structure of a1b2g1 regulatory core plus the KD (Xiao et al., 2011) . In addition to revealing the location of the activation loop and active site of the a subunit in relation to nucleotide binding sites in the g subunit, these investigations revealed that the AID of the a subunit adopts a unique position relative to the conformation observed in a nonactivated homolog from yeast (Chen et al., 2009 (Chen et al., , 2013 . This allows a flanking regulatory segment (aRIM) to directly interact with bound nucleotides in the g subunit, establishing a line of communication between AMP and the a subunit. A landmark structure was recently reported by Xiao et al. in December 2013 describing the first near full-length structure of any AMPK isoform (a2b1g1) (Xiao et al., 2013) . This work revealed the topology of this heterotrimer in a ligand-bound state and revealed a role for an intersubunit interface between a2 and b1 for binding of synthetic activators (see Results/Discussion). In this study, we extend the collection of AMPK structures by providing the full length structure of the a1b1g1 isoform of mammalian AMPK containing the regulatory core, KD, and CBM. We determined structures in the presence and absence of synthetic activators to better understand the conformations and molecular mechanisms associated with activator binding. The crystal structures reported herein, along with kinetic and biophysical studies, demonstrate that AMP and A769662 engage distinct molecular mechanisms for activation of AMPK.
RESULTS

AMP-Activated Protein Kinase a1b1g1 Adopts an Extended Structure Capped by the Carbohydrate Binding Module of b1
We recognized the importance of the CBM motif for activator binding (Landgraf et al., 2013) and explored many AMPK constructs to achieve homogeneity with respect to posttranslational modifications. Our final construct (AMPK xtal ) is displayed in Figure 1A and represents a variant of rat a1b1g1 that includes replacement of a previously described flexible loop in the a1 subunit (Xiao et al., 2007) with a flexible linker, truncation of the first 67 residues of b1 (predicted to be unstructured), the phosphomimetic mutation, S108D, within the CBM of b1, and full-length g1. The resulting heterotrimer was phosphorylated on T172 in vitro using CaMKKb yielding a functional enzyme with activity comparable to full-length wild-type (WT), but nearly devoid of heterogeneity as assessed by mass spectrometry ( Figure S1 available online).
We crystallized AMPK xtal in the presence of AMP and staurosporine, a potent kinase inhibitor, and determined the structure at 3.4 Å resolution (Table 1) . a1b1g1 adopts an extended conformation similar to that seen for a2b1g1 (Figures 1 and 2) . The a and b subunits dock atop the g subunit where the C-terminal region of the b subunit is sandwiched between the top of the g domain and the C-terminal region of the a subunit. The KD of the a1 subunit is located against the core, and the activation loop encompassing pT172 is well ordered and positioned as previously described (Xiao et al., 2011) ( Figure S2A ). The C-helix of the KD adopts a conformation consistent with an active kinase in which a critical salt bridge between K45 and E64 is intact. The regulatory segment of the a subunit, which is partially modeled in a2b1g1, is disordered in our structure. The CBM of the b1 subunit sits atop the N-lobe of the KD of the a1 subunit, where each domain contributes a b sheet in a nearorthogonal orientation to create a clam-shell-shaped interface. The conformation and location of the CBM is similar to that observed for a2b1g1 (Figure 2 ), but differs dramatically from that observed for the yeast homolog, where the CBM was shown to interact with the g subunit (Amodeo et al., 2007) . The CBM-KD interface is stabilized by electrostatic interactions between two conserved lysines in the a1 subunit (K29, K31) and the phosphomimetic aspartic acid at position 108 of the b1 subunit ( Figure 1C ). Note that position 108 is a serine in WT AMPK, which can be phosphorylated in vivo (Mitchelhill et al., 1997; Warden et al., 2001; Woods et al., 2003b) . The S108D mutation led to greater homogeneity and, consequently, was the construct that first enabled crystallization. We have subsequently reinstated the native S108 and, after in vitro phosphorylation (>75% pS108), crystallized the pS108 a1b1g1 construct and collected a data set to 3.9 Å resolution. Although the lower resolution precluded extensive model building and refinement, maps were of sufficient quality to allow visualization of the phosphate in a difference electron-density map. The phosphate occupies a similar location as the carboxylate in S108D and generates an analogous orientation of the CBM-KD interface ( Figure S2B ). These observations confirm that the a/b interface observed in the S108D crystals is not an artifact of the phosphomimetic mutation. There is an additional sphere of electron density visible within the CBM-KD interface which we have modeled as a sulfate due to both its proximity to positively charged amino acids (a1K29, a1K51, b1R83) and the presence of > 1 M sulfate in the crystallization conditions ( Figure S3 ). This ion is likely a consequence of crystallization and not of physiological or mechanistic relevance. Additional weak density observed in this cavity is likely due to water or buffer components, which have not been modeled.
The b1 subunit further contributes a novel helical motif (recently termed the ''C-interacting helix''), which extends from the C-terminal end of the CBM and packs against the B-and C-helices of a1, generating a pseudo-helical bundle ( Figures  1B and S2C ). This helix has not been observed in previous studies of the isolated CBM, but was recently observed in a2b1g1 (Xiao et al., 2013) . The C-interacting helix comprises res- idues 162-171 and modeling resumes at residue 201 as the structure transitions into the core particle. There exists a stretch of partially continuous electron density (varying in clarity across structures), which likely accounts for a portion of this linker. We have attempted to build this segment, but have ultimately chosen to exclude it from the final model, as we were unconvinced of amino acid registration or identity. AMPK a1 and a2 share a sequence identity of 77%, and the global architecture between the a1b1g1 and a2b1g1 structures appears highly conserved. Overall shape and topology are alike, with docking of the CBM of the b subunit atop the KD (Figure 2A ). Both structures contain an ordered C-interacting helix which packs against the N-lobe of a1 or a2, and both structures contain an active conformation of the regulatory spine as seen in other kinases ( Figure 2B ) (Taylor and Kornev, 2011) . Despite these similarities, these structures possess several important differences. First, although the a2b1g1 structure contains the phosphorylated activation loop (pT172), and is bound to an activator, a critical salt bridge between K45 and E64 in the N-lobe is broken due to displacement of the aB and aC helices of a2 ( Figure 2C ). This salt bridge is thought to be a requisite for a catalytically competent kinase and is maintained in our a1b1g1 structures. In addition, the KD and CBM are significantly offset with respect to the regulatory core. This is caused by a 15 rigid body rotation near the base of the KD ( Figure 2D ). With alignment based on the N-lobe of the KD, we see that although the overall shape of the CBM-KD interface is preserved, the b1 CBM docks differently atop a1 versus a2 ( Figure 2E ). Although slight variation occurs even within the a2b1g1 structure between the two copies in the asymmetric unit, differences are more pronounced in comparisons between a1b1g1 and a2b1g1 (global root-meansquare deviation [rmsd] 1.5 Å ).
A769662
Binds at a Novel a/b Allosteric Site AMPK a1b1g1 was initially crystallized in the presence of AMP, but in the absence of the synthetic activator, A769662.
Examination of the g subunit reveals weak electron density in at least three of the four nucleotide binding sites (sites 1, 3, 4). We have modeled an AMP at site 4 (high affinity) in all structures, but, given the limited diffraction resolution data, we have modeled either nucleotide or sulfate in sites 1 and 3 depending on the quality of the electron density map (although this may actually represent weak/partial density for nucleotide). In one instance, we have cautiously modeled an ADP in site 1 (which is likely a contaminant in our AMP stock), though it is conceivable that partial occupancy of AMP and/or sulfate could also be present.
To characterize binding of the synthetic activator, A769662, we turned to a chlorinated analog (termed Cl-A769662), which differs from the parent compound by a single atom (Cl) appended directly to the thienopyridone core. Cl-A769662 binds and activates a1b1g1 with higher affinity/potency (7-fold) than A769662 and afforded the opportunity to obtain an activator-bound structure at 3.3 Å resolution through a crystal soaking experiment (Figures 3 and 4A ). Cl-A769662 binds to a1b1g1 at the interface between the CBM and the KD, similar to the binding site observed in the A769662 complex with a2b1g1. This site is at the opposite pole of AMPK from the nucleotide binding sites and contacts neither the ATP site nor activation loop of the KD.
Cl-A769662 docks such that the hydroxyl of the thienopyridone core is positioned to interact with K29 of a1, while the carbonyl is positioned to form a hydrogen bond with K51 of a1.
The intervening nitrile group faces solvent and likely perturbs the pK a of the adjacent hydroxyl, increasing its acidity. The nitrogen of the pyridone core donates a hydrogen bond to D88 of a1 and disrupts an electrostatic interaction between D88 (a1) and R83 (b1) observed in the apo structure (Figures 3 and S4) . The repositioned R83 stacks 4 Å above the Cl-A769662 core, forming a p-cation interaction with the ligand, contributing to its overall free energy of binding. In addition, the side chain guanidinium group of R83 forms an ion-pair with a1 D217 from a neighboring molecule in the crystal. From the bottom, I46 of a1 forms a pedestal upon which the 6-5 core of the ligand rests. The central phenyl ring occupies a narrow channel, which is lined in the back by hydrophobic residues and in the front by K31. K31 participates in two additional interactions; it simultaneously forms an electrostatic interaction with D108 of b1 and donates a hydrogen bond to the hydroxyl group of the phenol in the tailpiece of Cl-A769662. This phenolic oxygen participates in a bifurcated interaction in which it additionally donates a hydrogen bond to the backbone carbonyl of G19 of a1. Together, a network of hydrophobic and polar interactions serves to anchor Cl-A769662 at the CBM-KD interface.
To better understand the structure-activity relationship of the A769662 series and to confirm the assignment and modeling of the allosteric binding site, we solved the structure of AMPK xtal in the presence of a dibromo analog of A769662 (Br 2 -A769662 core ) (Figure 4 ). The presence of two bromines enabled us to collect anomalous diffraction data that allowed for unambiguous placement of the ligand ( Figure S2D ). Evaluation of the AMPK xtal structures with Br 2 -A769662 core and Cl-A769662 reveals nearly identical poses for the thienopyridone core, confirming our previous interpretation of the electron density.
Comparison to the recent A769662-bound a2b1g1 structure reveals that in both isoforms, the core of the ligand is positioned with a remarkably similar pose ( Figure 3C ). These similarities occur even though the a1b1g1 structure represents a soaking experiment, while the a2b1g1 structure was generated by cocrystallization and is in-line with the high level of sequence identity (93%) between the N-lobes of a1 and a2 including absolute conservation of residues contacting ligand. As this structure represents an improvement in resolution relative to the a2b1g1 structure with A769662 (3.35 Å versus 3.9 Å ), we were able to examine the binding mode in additional detail.
Ligand Deconstruction Allows Probing of the Allosteric Pocket To map the importance of different regions of the allosteric pocket for ligand binding, we investigated binding of four analogs of A769662 differing in the nature of the tailpiece and halogen appended to the core ( Figure 4A ). The highest binding affinity, as determined by surface plasmon resonance (SPR) in the presence of AMP, is observed for Cl-A769662, which provides a modest (7-fold) increase in potency relative to parent (A769662). The small potency boost is likely explained by the burial of the chlorine within a small hydrophobic pocket comprised primarily of residues F90 from a1 and V81, V113, and I115 of b1. The phenol plays a prominent role in binding affinity through both the bifurcated hydrogen bonds with K31 and G19 of a1 and through van der Waals interactions with the CBM and KD. As such, deletion of the phenol produces an The bromine atom at the para position of the central phenyl ring projects along the same trajectory as the phenol, but is unable to fulfill hydrogen bonding. This defect is partially rescued by the second bromine on the thienopyridone core, which occupies the same hydrophobic pocket as the chlorine.
Solution Studies Validate Crystallographic Observations
Prior mutagenesis studies have revealed that deletion of the CBM or KD abolishes AMPK activation by A769662 (Gö ransson et al., 2007; Sanders et al., 2007; Scott et al., 2008; Xiao et al., 2013) . However, in contrast to a previous report (Scott et al., 2008) , we observe interactions between A769662 and isolated b1 CBM in solution, albeit weak. Nuclear magnetic resonance (NMR) TROSY experiments using 15 N b1 CBM reveal a subset of residues that undergo chemical-shift perturbations in the presence of A769662 (Figures 5A and S5) . Mapping these onto our structure shows that the residues with the greatest effect cluster in and around the allosteric binding site ( Figure 5A ). Close inspection shows that several of the amino acids in this vicinity are not conserved between b1 and b2. Although A769662 has been observed to bind to b2-containing heterotrimers (Landgraf et al., 2013) and provide some protection of pT172 from dephosphorylation (Hawley et al., 2012) , it is a weaker activator of b2-isoforms in biochemical assays (Sanders et al., 2007; Scott et al., 2008; Xiao et al., 2013) . We reasoned therefore that generating chimeras in which we swapped amino acids from b1 to b2 and vice versa may lead to enzymes with altered functional specificity. Indeed, swapping only three of the nonconserved amino acids (F82I, T85S, and G86E) was sufficient to greatly diminish A769662 potency toward b1, but greatly increase potency toward b2 ( Figure 5B ). These chimeras do not fundamentally alter intrinsic AMPK activity, as their response to AMP, which binds in the g subunit, remains largely unchanged. None of these three amino acids directly contacts ligand. Instead, they are proximal to or in contact with ligand-coordinating residues. The effects of these mutations may therefore reflect subtle changes in structure, dynamics, or topology of the CBM-KD interface that differ between b1 and b2.
We next assessed the relative importance of interface electrostatics. First, we generated a triple mutant in which the three interface lysines of the a subunit were converted to glutamines (K29-31-51Q) and assayed this mutant side-by-side with WT AMPK. Heterotrimeric K29-31-51Q retained intrinsic activity comparable to WT a1b1g1 (data not shown), but failed to interact with A769662 up to the highest concentration tested (1 mM) (Figure 6 ). This result is similar to mutagenesis data reported for the a2b1g1 isoform (Xiao et al., 2013) . Next, we investigate an earlier report demonstrating that mutation of serine 108 to alanine (S108A) greatly diminishes interaction with A769662 (Sanders et al., 2007) . We expanded this result by performing a more conservative comparison between serine and phospho-serine at position 108, reflecting the two likely chemical forms of this residue in vivo (Mitchelhill et al., 1997) . In short, we performed in vitro phosphorylation reactions of AMPK and quenched the reaction at distinct time points to generate samples of protein that were highly phosphorylated on T172 within the activation loop of the a1 subunit, but varied in the extent of phosphorylation on S108 of b1. In contrast to the S108A mutation, which nearly abolished activation, AMPK reagents with S108 or pS108 appear to respond to A769662 to similar extent ( Figure S6 ). Lastly, we generated a set of AMPK truncation variants to probe the extent to which activation by AMP and A769662 are dependent on regulatory domains ( Figure S6) . Deletion of the CBM of the b1 subunit does not alter activation by AMP, consistent with the known location of nucleotide binding sites in the g subunit. In contrast, A769662 is unable to activate the DCBM variant, in agreement with prior reports (Gö ransson et al., 2007; Sanders et al., 2007; Scott et al., 2008; Xiao et al., 2013) and in support of our crystallographic observations of the allosteric binding site at the CBM-KD interface. We generated an additional variant termed DaRIM, in which we deleted a 62 amino acid segment (333-394) in the a subunit comprising aRIM1/2, along with flanking amino acids. The deleted segment was replaced with a nine-amino acid (AAGGPGGAA) linker, yielding a well behaved heterotrimer with intrinsic activity similar to WT ( Figure S6 ). While this variant was fully activated by A769662, it was largely insensitive to activation by AMP, consistent with previous site-directed mutagenesis (Chen et al., 2009 ).
A769662 and AMP Exert Distinct Kinetic Effects on AMPK
To probe the kinetic mechanism, we performed in vitro assays monitoring the phosphorylation of a model peptide substrate (SAMS peptide) derived from acetyl-CoA carboxylase 1 (Davies et al., 1989) . Experiments were performed under saturating concentrations of ATP while varying the concentration of SAMS peptide in the presence or absence of AMP or A769662 ( Figure 7A ). Though effects of AMP are complicated by the presence of multiple binding sites and potential interactions of ATP at these sites, we nevertheless observe 2-fold increase in reaction V max with no effect on K m for SAMS peptide. This result is similar to an . In contrast, A769662 mediates its effect primarily through decreasing K m (for SAMS peptide) 4-fold, while exerting only a modest (1.4-fold) effect on V max . We also performed the reverse experiment where we used saturating levels of SAMS peptide while varying the ATP concentration. In this case, neither AMP nor A769662 had a significant effect on the K m of ATP (data not shown). Figure 7B shows the location of the allosteric site relative to the previously mapped substrate binding groove (Scott et al., 2002) .
DISCUSSION
The importance of the synthetic activator A769662 for the AMPK field is evident from the > 300 citations garnered since its initial disclosure in 2006 (Cool et al., 2006) . Despite a decade of advances in AMPK structural biology, the binding site for this ligand has remained elusive. Early studies following the A769662 disclosure discovered that the CBM of the b subunit was necessary for its interaction. Furthermore, a preference was noted for b1 over b2, and a hot spot within this domain was identified to lie at or near S108 (Gö ransson et al., 2007; Sanders et al., 2007; Scott et al., 2008) . However, inspection of structures of the isolated CBM motif revealed that S108 lies at a solvent-exposed surface that reveals no obvious pocket (Polekhina et al., 2005) . Consistent with this observation, the CBM domain alone is incapable of high affinity binding of A769662 as shown previously (Scott et al., 2008) and as indicated by weak interactions in our current solution NMR studies. A clue to the A769662 binding site emerged from recent work in which we investigated fulllength AMPK in solution by hydrogen-deuterium exchange (HDX) methods (Landgraf et al., 2013) . Comparison of the HDX profiles in the presence and absence of A769662 revealed that in addition to the b1 CBM, significant perturbations were observed for a peptide in the N-lobe of the a1 KD, implicating its role for ligand binding. These HDX studies suggested that A769662 is likely to bind at the CBM-KD interface (Landgraf et al., 2013) . This was recently confirmed by the crystal structures of compound 991 and A769662 bound to a2b1g1 that revealed a novel allosteric pocket (Xiao et al., 2013) .
With ligand-bound structures in hand, we can begin to more fully understand historical observations. Although of critical importance, the CBM provides only one half of the binding site. For the allosteric pocket to form, both CBM and KD must be present as the ligand binds at the interface between them. Given the architecture of the AMPK heterotrimer, with the KD and CBM emanating separately from the regulatory core, only a full-length structure containing core, KD, and CBM could allow such an interface to assemble. Therefore, despite the important insights gained from many years of structural studies of AMPK fragments, subunits, and subcomplexes, none of these systems contained all the necessary pieces to visualize A769662 binding.
The crystallographically observed binding site is supported by a wealth of solution studies. First, using truncation constructs, we find that the b1-CBM is essential for AMPK activation by A769662 ( Figure S6 ), consistent with prior reports (Gö ransson et al., 2007; Sanders et al., 2007; Scott et al., 2008; Xiao et al., 2013) . Our 2D-NMR experiments show that addition of A769662 alters the chemical shifts of a small subset of CBM residues, which cluster around the allosteric site (Figures 5 and S5 ). As A769662 preferentially activates b1-containing AMPK complexes (Sanders et al., 2007; Scott et al., 2008) , we reasoned that specificity is likely affected by CBM residues proximal to this interface. Indeed, chimeras in which residues from this surface are swapped between b1 and b2 demonstrate altered ligand specificity ( Figure 5 ). On the other side of the interface, we see a collection of electrostatic interactions involving three surface lysines, K29/31/51 with both A769662 and the b1-CBM. These amino acids are conserved between a1 and a2 and are retained in species ranging from worm to man. Finally, SPR binding studies of A769662 analogs reveal structureactivity relationships consistent with the observed binding mode (Figures 3 and 4) .
Our apo and holo a1b1g1 structures complement the recent disclosure of the structure of a2b1g1 bound to A769662 (Xiao et al., 2013) and begin the process of elucidating the structural basis of subtype-specific functions of different forms of AMPK. Although the previous reported structure of a2b1g1 with a different AMPK activator (compound 991) was at 3.0 Å resolution, the structure with A769662 was at considerably lower resolution (3.9 Å ). Comparison of the two isoforms (and both apo and holo structures) reveals a similar interface between the KD and CBM involving electrostatic interactions between pS/ D108 of the b subunit and K31/K29 of the a1 and a2 subunits, as well as a conserved conformation of the recently identified C-interacting helix. As the C-interacting helix forms a bundle with the aB and aC helices, we postulate that formation of this motif is dependent on maintenance of the a/b interface and is unlikely to be structured if the CBM dissociates. Finally, in both isoforms, the thienopyridone core of the ligand is positioned with a similar pose despite the fact that our ligand was modeled independently and prior to publication of the a2b1g1 structure ( Figure 3C ).
Despite these similarities, these structures possess several important differences. First, in the a2b1g1 structure a critical salt bridge in the KD (K45-E64) is broken, while it is maintained in our apo and ligand-bound a1b1g1 structures. In addition, with respect to the regulatory core, the position of the KD and CBM are significantly offset (Figure 2) . A third difference lies in the AID/a-RIM regulatory motif of the a subunit. In the a2b1g1 structure, this motif adopts a conformation similar to that previously observed in the structure of the regulatory core + KD (Chen et al., 2013; Xiao et al., 2011) . In our a1b1g1 structures, this regulatory segment is disordered, providing further support that it may sample an ensemble of conformations. Nevertheless, the observed conformation of the C-interacting helix allows us to rule out the possibility that the AID adopts the structure seen previously in an inactive homolog from yeast (Chen et al., 2009) (Figure S7 ).
The observed structural differences could be due to crystal packing or may reflect true diversity in the conformations of the a1b1g1 versus a2b1g1 isoforms. In addition, this may simply reflect structural plasticity within the many moving parts of this molecular machine such that we observe two states among the multitude of possible conformations. Understanding these differences may provide unique opportunities for the design of isoform-specific activators.
In this work, we determined the first structure of mammalian AMPK with all functional domains in the absence of a synthetic activator (apo). This structure reveals that the CBM is able to dock atop the KD even in the absence of ligand and demonstrates that binding of A769662, or other potent ligands, is not a prerequisite for formation of the allosteric site. Rather, the CBM-KD interface represents one of many naturally occurring conformations of AMPK in solution. This is consistent with recent work establishing that the autophosphorylation of S108 occurs in cis, i.e., phosphorylation occurs within a heterotrimeric complex (Scott et al., 2014) . As Ser 108 of the b subunit in the present structure lies outside the substrate binding groove, flexibility and rearrangement must occur for cis auto-phosphorylation to take place.
Our crystallographic and solution studies suggest fundamentally different molecular mechanisms of AMPK activation elicited by A769662 and AMP. The AMP binding sites on the g subunit are 50 Å away from pThr172 on the activation loop of the a subunit KD. There are distinct structural changes that are observed in the g subunit, especially around site 3 between ATP-and AMP-bound forms. These perturbations are likely to result in altered conformation of the a-RIM, which forms direct interaction with the g subunit near this site (Chen et al., 2013; Xiao et al., 2011 Xiao et al., , 2013 . These perturbations are in turn conveyed to the activation loop of the kinase by long-range allosteric effects via the AID module. Consequently, the pThr172 site becomes less accessible to phosphatases on binding of AMP, which may account for the observed protection from dephosphorylation. In addition, our kinetic studies show that AMP increases the V max of the phosphorylation reaction and may help fine-tune the kinase for optimized phosphoryl-transfer.
In contrast, the binding site for A769662 is located only 20 Å from the pThr172 site within the activation loop. Binding of A769662 at the allosteric site is likely to stabilize the active conformation of the B-and C-helices of the KD via the C-interacting helix. This may also help displace the AID from the KD to relieve a previously described auto-inhibition event (Chen et al., 2009) (Figure S7 ). Our kinetic data show that A769662 activates AMPK by lowering the K m for SAMS peptide (4-fold) with only a small effect on the reaction V max . Although the limited diffraction resolution of our structures does not allow for a detailed analysis of the structural differences, the kinetic data imply that binding of A769662 leads to subtle structural changes that result in a more optimal binding of the SAMS peptide. Another possible explanation is that binding of A769662 shifts the equilibrium toward the active conformation of AMPK via stabilization of the CBM-KD interface. Both of these explanations are consistent with recent results showing that A769662 protects portions of the substrate binding site from exchange with deuterium (Landgraf et al., 2013) . Regardless, the molecular mechanism that underlies AMPK activation by the synthetic activator A769662 is radically different from that employed by the endogenous activator, AMP.
It is tempting to speculate that in addition to A769662, other ligands might take advantage of this site to bind and modulate AMPK activity. Recently, it has been shown that salicylate, an active metabolite of aspirin, binds to and directly activates AMPK in a manner that is competitive with A769662 (Hawley et al., 2012 ). Although we were unable to obtain a high-resolution In yellow are seven residues (D56, E100, D103, L212, D215, D216, D217) from previous mutation analysis used to map substrate binding (Scott et al., 2002) . Errors denote ± SD of the fit. See also Figure S7 .
structure of AMPK with salicylate bound, anomalous diffraction data from an iodinated variant (5-iodosalicylate) supports that salicylate binds at the CBM-KD interface (Figure 8 ). The experimental electron density for the iodine lies just below the pS/D108 loop and would roughly overlay with the position of the phenol of Cl-A769662 in our structure. While the identification of a physiological ligand for the CBM-KD allosteric site remains to be revealed, we hypothesize that AMPK may be a broad energy sensor, responding to changes in levels of nucleotides, carbohydrate, and other metabolic mediators.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification AMPK a1b1g1 was cloned into a tricistronic vector containing a His-tag at the N terminus of the a subunit (Neumann et al., 2003; Rajamohan et al., 2010) . Constructs were generated using standard molecular biology techniques and are described as follows: The a chain of AMPK xtal was comprised of a 22-residue N-terminal tag (MPRAHHHHHHAAGENLYFQGAT) that included an initation Met, a hexahistidine-tag, and a tobacco etch virus (TEV) protease cleavage site, followed sequentially by residues 2-469 of GenBank accession code U40819.1, an eight-residue linker (ASGGPGGS), and residues 525-548 of GenBank accession U40819.1. The b1 chain was comprised of an initiator methionine followed by residues 68-270 of UniProt accession P80386, except that S108 was mutated to D. The sequence of the g chain was identical to the 330-residue sequence of UniProt accession P80358. Biochemical and biophysical experiments used full-length human AMPK a1b1g1 with an N-terminal Histag on the a subunit. For SPR binding experiments, an additional biotinylated biotin-acceptor-peptide (BAP) was included at the N terminus of the g subunit. For expression, plasmids were transformed into E. coli BL21-CodonPlus cells grown at 37 C and induced with 0.1 mM isopropyl b-D-1-thiogalactopyranoside at 18 C overnight. Cell pellets were resuspended in 25 mM Tris 7.5, 300 mM NaCl, 10% glycerol, 2 mM phosphanetriyltripropanoic acid (TCEP), 40 mM imidazole, and lysed by three passages through a microfluidizer at 18k pounds per square inch. Lysate was cleared by centrifugation, passed over HiTrap Ni-NTA resin, and eluted with imidazole. Protein was dialyzed overnight in the presence of TEV protease to remove the His-tag (only for crystallization). AMPK was phosphorylated with CaMKKb in the presence of calmodulin and Mg-ATP and subsequently purified over Ni-NTA (activity assays) or ion exchange and size-exclusion chromatography (crystallography and biophysics). Purity was assessed by SDS-PAGE and mass spectrometry ( Figure S1 ).
Crystallization and Refinement AMPK xtal at 10-15 mg/ml in 25 mM Tris 7.5, 150 mM NaCl, 2 mM TCEP, 10%
glycerol, was incubated with 400 mM of both AMP and staurosporine for 10 min on ice. This mixture was then centrifuged and mixed 1:1 with well buffer (750 mM ammonium sulfate, 500 mM lithium sulfate, 100 mM trisodium citrate, 1% ethylene glycol) in sitting drops and incubated at 22 C. Crystals appeared after 3-7 days and were frozen in mother liquor plus 30% glycerol. Data were collected at IMCA-CAT and GMCA-CAT at Advanced Photon Source (APS) as well as beamline 5.0.1 at Advanced Light Source. Data sets were processed using HKL2000 (Otwinowski and Minor, 1997) . The structure was determined by molecular replacement using PHASER (McCoy et al., 2007) with domains derived from 2Y94.pdb (Xiao et al., 2011) and 1Z0M.pdb (Polekhina et al., 2005) as search models. Refinement and rebuilding were carried out using autoBUSTER (Blanc et al., 2004) , PHENIX (Adams et al., 2010) , and Coot (Emsley and Cowtan, 2004) , and figures were generated using PyMOL (Schrodinger, version 1.2r3pre).
For the structures in the presence of Cl-A769662 and Br 2 -A769662 core , crystals were soaked overnight in mother liquor with 500 mM ligand, 400 mM AMP, and 200 mM staurosporine, along with 10% glycerol. Crystals were frozen in this soak solution supplemented with 30% glycerol, and the structure was solved by molecular replacement using the apo structure as a search model.
Kinase Activity Measurements
The kinase activity of recombinant AMPK samples was monitored in vitro by phosphorylation of the SAMS peptide as previously described (Rajamohan et al., 2010) . Where described, AC 50 values reported for A769662 and AMP were measured in the presence of 0.25 nM AMPK in assay buffer, and all experiments were performed in triplicate with each half maximal activating concentration (AC 50 ) value representing the mean of three experiments. Steady state kinetic parameters were determined by measuring the kinase activity of AMPK via AMPK-mediated incorporation of 33 P-phosphate from [ 33 P g ]ATP into the synthetic SAMS peptide (Davies et al., 1989) . This peptide has the amino acid sequence HMRSAMSGLHLVKRR and is derived from residues 73-85 of rat acetyl-CoA carboxylase 1 in which Ser77 is mutated to Ala and the phosphorylation site is Ser79. Under acidic conditions, the phosphorylated product was retained on the filter via charge interaction while [ 33 P]ATP was removed by filtration. Captured product was then measured by coincident liquid scintillation counting using a PerkinElmer MicroBeta Trilux. Standard kinase reactions were performed in assay buffer consisting of 50 mM HEPES, pH 7.5, 1 mM EGTA, 10 mM MgCl 2 , 0.25 mM dithiothreitol, 0.01% Tween-20, and 0.01% BSA. There were eight concentrations of the SAMS peptide substrate that were tested in a serial one-to-one dilution scheme, while keeping ATP fixed at 10-fold the K M -value (200 mM) with and without 10 mM AMP or 10 mM A769662. The specific activity of [ 33 P]ATP was maintained at 0.25 mCi/ nmol. These assays were assembled by the addition of 30 ml of AMPK to 10 ml of a 4-fold concentrated substrate mix. Assay linearity was ensured in separate experiments by determining that < 30% substrate was depleted for all concentrations tested. The reactions were incubated for 60 min at room temperature and were terminated by the addition of 15 ml of 2% phosphoric acid, followed by washing three times with 100 ml assay buffer containing 0.1% Tween-20.
Plates were allowed to dry prior to the addition of 25 ml of Ready Safe scintillation fluid (141329, Beckman Coulter), followed by liquid scintillation counting.
Surface Plasmon Resonance Experiments
Experiments were performed on a Biacore TM 3000 instrument (GE Healthcare).
BAP-tagged AMPK a1b1g1 was captured onto a streptavidin sensor chip to levels ranging from 4,000-6,000 response units. Binding experiments were Figure 8 . Salicylate Binding at the Allosteric Site
Anomalous difference map at 3.9 Å resolution contoured at 4 s. Crystal of AMPK xtal was soaked with 2 mM 5-iodosalicylate overnight before flash freezing. The strongest peaks in the asymmetric unit localize to the allosteric site. 2fo-fc density was not sufficient to permit modeling of the compound.
performed in 25 mM Tris, pH 7.5, 150 mM NaCl, 250 mM TCEP, 0.01% P20, 0.5 mg/ml BSA, 2% DMSO and ± 150 mM AMP at 25 C (Supplemental Experimental Procedures).
Nuclear Magnetic Resonance Spectroscopy
The NMR TROSY spectra were collected on a Bruker spectrometer equipped with a 1.7 mm micro cryoprobe operating at 600.33 MHz. The NMR samples contained 5 mg/ml of 15 N uniformly labeled b1 CBM in 25 mM phosphate buffer, pH 7.5, and 0.02% sodium azide (Supplemental Experimental Procedures).
ACCESSION NUMBERS
Coordinates and structure factors have been deposited in the Protein Data Bank under ID codes 4QFG, 4QFR, and 4QFS. 
